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Abstract
Background: Repetitive	Transcranial	Magnetic	Stimulation	 (rTMS)	 is	commonly	ad‐
ministered	to	Major	Depressive	Disorder	(MDD)	patients	taking	psychotropic	medi‐
cations,	yet	the	effects	on	treatment	outcomes	remain	unknown.	We	explored	how	
concomitant	medication	use	relates	to	clinical	response	to	a	standard	course	of	rTMS.
Methods: Medications	were	tabulated	for	181	MDD	patients	who	underwent	a	six‐
week	rTMS	treatment	course.	All	patients	received	10	Hz	rTMS	administered	to	left	
dorsolateral	prefrontal	cortex	(DLPFC),	with	1	Hz	administered	to	right	DLPFC	in	pa‐
tients with inadequate response to and/or intolerance of left‐sided stimulation. 
Primary outcomes were change in Inventory of Depressive Symptomatology Self 
Report	(IDS‐SR30)	total	score	after	2,	4,	and	6	weeks.
Results: Use	of	benzodiazepines	was	associated	with	 less	 improvement	at	week	2,	
whereas use of psychostimulants was associated with greater improvement at week 
2	and	across	6	weeks.	These	effects	were	significant	controlling	for	baseline	varia‐
bles	 including	 age,	 overall	 symptom	 severity,	 and	 severity	 of	 anxiety	 symptoms.	
Response	 rates	 at	 week	 6	 were	 lower	 in	 benzodiazepine	 users	 versus	 non‐users	
(16.4%	vs.	35.5%,	p	=	0.008),	and	higher	in	psychostimulant	users	versus	non‐users	
(39.2%	vs.	22.0%,	p	=	0.02).
Conclusions: Concomitant	 medication	 use	 may	 impact	 rTMS	 treatment	 outcome.	
While	the	differences	reported	here	could	be	considered	clinically	significant,	results	
were not corrected for multiple comparisons and findings should be replicated be‐
fore	clinicians	incorporate	the	evidence	into	clinical	practice.	Prospective,	hypothe‐
sis‐based treatment studies will aid in determining causal relationships between 
medication treatments and outcome.
K E Y W O R D S
adrenergic,	benzodiazepines,	gamma‐aminobutyric	acid	(GABA),	Major	Depressive	Disorder,	
psychostimulants,	repetitive	transcranial	magnetic	stimulation	(rTMS),	treatment	outcome
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1  | INTRODUC TION
Repetitive	 Transcranial	 Magnetic	 Stimulation	 (rTMS)	 has	 gained	
increasingly	 widespread	 clinical	 use	 for	 treatment	 of	 Major	
Depressive	 Disorder	 (MDD)	 since	 it	 was	 approved	 in	 the	 US	 in	
2008	for	treatment	of	antidepressant	drug‐resistant	unipolar	major	
depression.	Although	 initial	 trials	 examined	 the	 efficacy	 of	 rTMS	
monotherapy	for	MDD	(George	et	al.,	2010;	Levkovitz	et	al.,	2015;	
O'Reardon	et	al.,	2007),	in	clinical	practice	physicians	typically	ad‐
minister	rTMS	as	an	augmentation	therapy,	rather	than	discontinue	
a patient's current medications. Several studies have confirmed the 
clinical	effectiveness	of	rTMS	in	patients	who	are	taking	adjunctive	
antidepressants	 (Carpenter	 et	 al.,	 2012;	George,	 Taylor,	&	 Short,	
2013)	or	have	examined	the	effects	of	initiating	rTMS	for	a	brief	pe‐
riod at the outset of treatment with antidepressant medication as 
a	means	of	bolstering	medication	response	(Berlim,	den	Eynde	Van,	
&	Daskalakis,	2013).	However,	none	have	examined	the	effects	of	
different	classes	of	medication	on	rTMS	treatment	outcome.
Clinical guidelines presently address concomitant medication use 
solely from a safety perspective. Caution is advised when adminis‐
tering	 rTMS	 to	 patients	who	 are	 taking	 stimulants	 or	 other	medi‐
cations	 that	may	 lower	 seizure	 threshold,	 or	 following	 a	 decrease	
or	discontinuation	of	antiepileptics,	benzodiazepines,	or	other	med‐
ications	 with	 anticonvulsant	 properties	 (McClintock	 et	 al.,	 2018).	
A	recent	consensus	states	that	“TMS	therapy	can	be	administered	
in the presence or absence of concurrent antidepressant or other 
psychotropic	medications”	(Perera	et	al.,	2016).	Although	there	are	
no	reports	of	rTMS	clinical	outcomes	 in	relationship	to	concurrent	
medications,	 experimental	 pharmaco‐TMS‐EEG	 studies	 in	 single‐	
or paired‐pulse paradigms have routinely demonstrated effects of 
central	 nervous	 system	drugs	 on	measures	 of	 cortical	 excitability,	
connectivity,	and	plasticity	(Ziemann,	2004).	Given	that	therapeutic	
effects	 of	 rTMS	 are	 posited	 to	 result	 from	 long‐term	potentiation	
(LTP)	or	long‐term	depression	(LTD)‐like	effects	in	critical	brain	cir‐
cuits	(Kobayashi	et	al.,	2017;	Ziemann	et	al.,	2015),	it	is	reasonable	to	
hypothesize	that	concurrent	psychotropic	medications	could	 influ‐
ence clinical outcome.
The	 present	 study	 explored	 associations	 between	 concomi‐
tant	medications	 and	 rTMS	 outcome	 during	 treatment	 of	MDD.	
The	motivation	for	this	investigation	was	twofold:	first,	to	exam‐
ine evidence that could help inform clinical decision‐making when 
addressing	 the	 integration	 of	 psychopharmacology	 with	 rTMS;	
and	 second,	 to	 identify	 those	medication	mechanisms	 of	 action	
(MOAs)	 that	might	 help	 elucidate	which	 classes	 of	 psychotropic	
drugs	are	most	likely	to	interact	with	rTMS	effects.	We	therefore	
examined	the	effect	of	standard	medication	classes	on	treatment	
outcome	 in	 181	 patients	 receiving	 a	 standard	 clinical	 course	 of	
rTMS.	 In	 supplementary	 analyses	 (Data	 S1),	 we	 also	 examined	
the	effects	of	medication	on	outcome	using	a	novel	MOA‐based	
schema based on the neurochemical actions of individual drugs. 
Results identified categories of medication use that were associ‐
ated with greater or lesser clinical improvement over the course 
of	rTMS.
2  | METHOD
2.1 | Overview and subjects
This	retrospective	chart	study	was	undertaken	to	examine	potential	
relationships between categories of medication use and clinical out‐
come	to	rTMS	treatment	for	depression.	There	were	no	experimen‐
tal	manipulations;	 rTMS	 treatment	 and	medication	 data	 collection	
were performed naturalistically.
Subjects	 (n	=	227)	were	 all	 patients	 treated	 in	 the	 TMS	UCLA	
Clinical and Research Program between September 2009 and 
January	2017	and	who	provided	written	 informed	consent	 to	par‐
ticipate	in	this	UCLA	IRB‐approved	study.	Subjects	were	treated	in	
accordance	with	the	2013	Declaration	of	Helsinki.	Analyses	included	
subjects	 who	 had	 baseline	 medication	 data	 available,	 received	 at	
least	10	rTMS	treatment	sessions	for	non‐psychotic	MDD,	and	were	
assessed at baseline using the 30‐item Inventory of Depressive 
Symptomatology	 Self	 Report	 (IDS‐SR30)	 (Rush,	 Gullion,	 Basco,	
Jarrett,	&	Trivedi,	1996).	Figure	1	shows	a	data	flow	diagram	of	the	
analyzable	sample	(n	=	181).
2.2 | Medication categories
Medications	were	classified	according	to	drug	classes	(Table	1)	using	
13	 mutually	 exclusive	 categories:	 Selective	 Serotonin	 Reuptake	
Inhibitors	 (SSRI);	 Serotonin‐Norepinephrine	 Reuptake	 Inhibitors	
(SNRI);	 Tricyclic	 antidepressants	 (TCA);	 Monoamine	 oxidase	 in‐
hibitors	 (MAOIs);	 Atypical	 antidepressants;	 Atypical	 antipsychot‐
ics;	 Typical	 antipsychotics;	 Antiepileptics	 (AED);	 Benzodiazepines	
(BDZ);	 Quasi‐benzodiazepines	 (QBDZ);	 Psychostimulants;	 Lithium;	
and	“Other.”	The	“Other”	medication	class	was	heterogeneous	and	
included	opiates,	thyroid,	melatonin,	and	memantine.	These	medica‐
tions	do	not	have	clear	effects	on	cortical	excitability	or	plasticity,	
and	 excepting	 thyroid	 hormone,	 they	 lack	 established	 antidepres‐
sant augmentation efficacy. Only seven subjects were taking thyroid 
hormone	at	study	entry.	An	alternate	classification	schema	also	ex‐
amined outcome in relation to use of medications grouped into eight 
non‐exclusive	categories	that	reflected	a	multiplicity	of	neurochemi‐
cal	MOAs	(Roth,	Sheffler,	&	Kroeze,	2004).	These	are	presented	in	
Data	S1.	Adherence	to	medications	was	confirmed	by	patient	report	
and verified by collateral history from their prescribing physicians.
2.3 | Subjects’ medication coding
Medication	 information	 for	 each	 subject	was	 obtained	 from	 elec‐
tronic records that listed all medications at the beginning of treat‐
ment.	Subject	data	were	coded	in	a	binary	“yes/no”	fashion	for	each	
category.	For	example,	a	subject	taking	only	venlafaxine,	would	have	
been	coded	as	 “1”	under	 the	 standard	 category	 “SNRI.”	For	medi‐
cations	 having	 dose‐dependent	 effects,	 each	 subject	 was	 coded	
as	warranted	by	 the	dose.	For	example,	 the	 following	medications	
were considered largely sub‐therapeutic and therefore lacking sig‐
nificant	effects	at	their	primary	targets,	at	the	following	daily	doses:	
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trazodone	(below	100	mg);	quetiapine	(below	100	mg);	venlafaxine	
(below	100	mg);	mirtazapine	(below	15	mg).	For	psychotropic	medi‐
cations	used	on	an	as‐needed	(prn)	basis,	we	estimated	the	average	
daily dose by patient report and then used our standard criteria. For 
those rare patients who started or stopped a medication during the 
course	of	 rTMS	 (approximately	5%),	we	 included	 them	 in	 that	 cat‐
egory	 as	 a	 conservative	measure.	 For	 each	 subject,	we	 computed	
“Total	number	of	medications,”	to	serve	as	general	measure	of	over‐
all medication use or burden.
2.4 | rTMS treatment
Subjects	 were	 treated	 using	 the	 NeuroStar	 TMS	 System	
(Neuronetics,	 Inc,	Malvern,	 PA)	with	30	 sessions	 scheduled	over	
F I G U R E  1   Data flow diagram of 
subject inclusion
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six	weeks.	Treatment	began	using	parameters	of	3,000	pulses	per	
session	 at	 10	Hz	 administered	 to	 the	 left	 dorsolateral	 prefrontal	
cortex	 (DLPFC)	 with	 a	 40‐pulse	 train	 and	 intertrain	 interval	 of	
26	s	(total	duration	37.5	min).	Intensity	was	titrated	up	to	120%	of	
the	resting	motor	threshold	(MT)	as	tolerated.	After	the	first	two	
weeks,	 “flexible‐dosing”	 adjustment	 options	 included:	 increasing	
the	number	of	10	Hz	pulses	delivered	to	the	left	DLPFC;	sequential	
bilateral	treatment	(Fitzgerald	et	al.,	2006)	with	addition	of	right‐
sided	1	Hz	stimulation	targeting	the	right	DLPFC;	or	switching	to	
1	Hz	stimulation	of	right	DLPFC	in	the	absence	of	benefit	from	bi‐
lateral	stimulation	 (McDonald	et	al.,	2011).	Within	these	options,	
up	to	5,000	total	pulses	were	delivered	per	session.	Treatment	ad‐
justments	were	guided	by	changes	in	symptom	severity,	and	phy‐
sician	 clinical	 judgment,	 within	 established	 treatment	 guidelines	
utilizing	a	“measurement‐based	care”	approach	(Guo	et	al.,	2015).
2.5 | Data analysis
Medication	categories	that	were	in	use	by	at	least	20%	of	the	sample	
were	examined	in	association	with	clinical	outcomes.	This	strategy	
reduced	the	number	of	tests	and	ensured	meaningfully	sized	analysis	
samples. Change in the IDS‐SR30 total score from baseline to week 
TA B L E  1  Medications	categorized	by	standard	classes
Standard category Medication name
SSRI Citalopram	(Celexa)
Escitalopram	(Lexapro)
Fluoxetine	(Prozac)
Fluvoxamine	(Luvox)
Paroxetine	(Paxil)
Sertraline	(Zoloft)
Vilazodone	(Viibryd)
SNRI Desvenlafaxine	(Pristiq)
Duloxetine	(Cymbalta)
Levomilnacipran	(Fetzima)
Venlafaxine	(Effexor	XR)
TCA Amitriptyline	(Elavil)
Clomipramine
Desipramine	(Norpramin)
Doxepin
Imipramine
Nortriptyline	(Pamelor)
MAOI Phenelzine
Selegiline	(Emsam)
Tranylcypromine	(Parnate)
Atypical	
Antidepressant
Bupropion	(Wellbutrin/Wellbutrin	SR)
Mirtazapine	(Remeron)
Nefazodone	(Serzone)
Trazodone	(Oleptro)
Vortioxetine	(Brintellix)
Atypical	
Antipsychotic
Aripiprazole	(Abilify)
Asenapine	(Saphris)
Lurasidone	(Latuda)
Olanzapine	(Zyprexa)
Quetiapine	(Seroquel)
Risperidone	(Risperdal)
Ziprasidone	(Geodon)
Typical	Antipsychotic Haloperidol	(Haldol)
Anti‐Epileptic Carbamazepine	(Tegretol)
Gabapentin	(Neurontin)
Lamotrigine	(Lamictal)
Oxcarbazepine
Pregabalin	(Lyrica)
Primidone	(Mysoline)
Topiramate	(Topamax)
Valproic	acid	(Depakote)
(Continues)
Standard category Medication name
Benzodiazepine Alprazolam	(Xanax/Niravam)
Chlordiazepoxide	(Librium)
Clonazepam	(Klonopin)
Diazepam	(Valium)
Lorazepam	(Ativan)
Temazepam	(Restoril)
Triazolam
Quazepam	(Doral)
Quasi‐Benzodiazepine Eszopiclone
Zolpidem
Psychostimulant Amphetamine/Dextroamphetamine	
(Adderall)
Armodafinil	(Nuvigil)
Dexmethylphenidate	(Focalin)
Dextroamphetamine	(Dexedrine)
Lisdexamfetamine	(Vyvanse)
Methylphenidate	(Concerta,	Ritalin,	
Methylin)
Modafinil	(Provigil)
Lithium Lithium
Other Amlodipine
Baclofen
Buspirone
Clonidine
Ephedrine
Prazosin
Propranolol
Tizanidine
Verapamil
TA B L E  1   (Continued)
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2,	 and	change	 in	 the	 IDS‐SR30	 total	 score	across	weeks	2,	4,	 and	
6,	were	examined	as	co‐primary	outcomes,	using	 linear	 regression	
and	 linear	mixed	model	 analysis,	 respectively.	 Analyses	were	 per‐
formed	using	SPSS	version	24;	because	this	was	an	exploratory,	hy‐
pothesis‐generating	investigation,	we	reported	all	findings	meeting	
a significance threshold of p	≤	0.05	without	correction	for	multiple	
comparisons.
The week 2 outcome was of specific interest because the first 
2 weeks were the most homogeneous with respect to treatment 
parameters	 including	 intensity	 (100%–120%	MT),	 “dose”	 (~3,000	
pulses),	 frequency	 (10	Hz),	 and	 site	 (i.e.,	 left	 DLPFC).	 Separate	
linear	regression	analyses	were	performed	to	examine	each	med‐
ication category as a dichotomous predictor of raw change in the 
IDS‐SR30	total	score	at	week	2,	in	models	that	included	the	base‐
line	 IDS‐SR30	 total	 score	 as	 a	 covariate.	 Medication	 categories	
that were identified as significant predictors after controlling for 
overall baseline severity were then evaluated in further models 
that	 examined	 baseline	 IDS‐SR30	 anxiety	 and	 non‐anxiety	 item	
totals	as	separate	covariates,	and	examined	covariates	of	age	and	
other	clinical	characteristics	(i.e.,	total	number	of	medications)	that	
differed between users and non‐users of a given medication cate‐
gory.	Baseline	anxiety	was	assessed	using	an	8‐item	subscale	(IDS‐
SR30	items	6,	23,	24,	25,	26,	27,	28,	30)	(Wardenaar	et	al.,	2010).	
In	statistical	models	that	examined	baseline	anxiety	as	a	covariate,	
IDS‐SR30	 item	 totals	were	 parsed	 into	 an	 anxiety	 subscale,	 and	
a	non‐anxiety	subscale	in	order	to	avoid	collinearity	between	the	
subscale and the total score.
Linear	mixed	model	analyses	were	used	to	assess	relationships	
between each medication category and change in IDS‐SR30 total 
score	over	6	weeks	of	treatment.	This	approach	was	used	to	exam‐
ine associations between medication use and response to clinical 
rTMS	more	generally,	 that	 is,	as	a	treatment	modality,	allowing	for	
variability	 and	 flexible	 changes	 in	 specific	 parameters.	 We	 com‐
pared symptom severity changes between users versus non‐users 
of	each	medication	category	in	separate	linear	mixed	model	analyses	
conducted	 using	 restricted	 maximum	 likelihood	 (REML).	 Changes	
in	 IDS‐SR30	total	score	at	weeks	2,	4,	and	6	were	calculated	from	
baseline,	 yielding	 a	 within‐group	 factor	 of	 time	with	 three	 levels.	
Mixed	models	examined	change	over	time,	co‐varying	for	baseline	
IDS‐SR30.	Other	covariates	were	examined	as	dictated	by	the	spe‐
cific medication category.
3  | RESULTS
3.1 | Clinical, demographic, and medication use 
characteristics of the sample
The	analyzable	sample	(n	=	181)	included	98	females	and	83	males	
with	 a	 mean	 age	 of	 46.6	±	16.6	years	 entering	 treatment	 with	 a	
mean	IDS‐SR30	total	score	of	42.8	±	11.1,	and	an	anxiety	subscale	
score	of	9.7	±	4.3.	Overall,	92%	of	subjects	were	taking	at	least	one	
psychotropic	medication;	78%	were	taking	at	least	one	antidepres‐
sant.	Among	medication	users,	the	mean	number	of	medications	was	
4.2	±	2.4,	 including	1.3	±	0.8	antidepressants.	Table	2	shows	medi‐
cation use by category. Seven of twelve clinically‐based medication 
categories	were	in	use	by	20%	or	more	of	the	sample.
3.2 | Clinical outcomes in the overall sample
Subjects	showed	a	mean	decrease	(improvement)	of	7.9	±	9.8	points	
on the IDS‐SR after 2 weeks of treatment. Change in symptom se‐
verity	at	week	2	was	not	associated	with	gender,	baseline	IDS‐SR30,	
baseline	anxiety,	or	total	number	of	psychotropic	or	antidepressant	
medications,	 but	 was	 significantly	 associated	 with	 age	 (p	=	0.04)	
where	older	subjects	showed	greater	 improvement.	After	6	weeks	
of	treatment,	subjects	improved	by	13.8	±	12.1	points.	Week	6	im‐
provement	was	associated	with	baseline	 IDS‐SR30	total	 (r	=	−0.27,	
p	=	0.001)	 and	 anxiety	 subscale	 (r	=	−0.16,	 p	=	0.05)	 scores,	 with	
higher	 baseline	 scores	 associated	 with	 greater	 decreases.	 47%	
of those who received solely left‐sided treatment responded to 
Medication category
Number of patients taking 
medication
Proportion (%) of the 
sample (n = 181)
SSRI 62 34.3
SNRI 42 23.2
TCA 9 5.0
MAOI 12 6.6
Atypical	Antidepressant 73 40.3
Atypical	Antipsychotic 56 30.9
Typical	Antipsychotic 1 0.6
Anti‐Epileptic 58 32.0
Benzodiazepine 72 39.8
Quasi‐benzodiazepine 16 8.8
Psychostimulant 56 30.9
Lithium 15 8.3
Other 30 16.6
TA B L E  2  Numbers	and	percentages	of	
patients taking medications during acute 
rTMS	treatment	for	depression,	grouped	
by	standard	non‐exclusive	categories
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treatment	 at	 week	 6,	 versus	 19%	 of	 those	 who	 had	 right‐side	
stimulation added at some point during their treatment course 
(χ2	=	13.386,	 p	<	0.001).	 Those	 patients	 who	 received	 right‐sided	
stimulation added also showed significantly smaller decreases in 
the IDS score total than those who had left‐sided stimulation only 
(t	=	3.033,	p	=	0.003).
3.3 | Medication categories and week 2 outcome
Regression	models	 for	 each	medication	 category,	 controlling	 for	
baseline	 IDS‐SR30,	 found	 significant	 effects	 for	 BDZs	 (p	=	0.02)	
and	 psychostimulants	 (p	=	0.05)	 (Table	 3a).	 BDZ	 use	was	 associ‐
ated	with	 less	 improvement	at	week	2,	whereas	psychostimulant	
use was associated with greater improvement. These medica‐
tion	 effects	 remained	 significant	 after	 adding	 covariates	 of	 age,	
baseline	anxiety,	and	total	number	of	medications	(Table	3b).	Age	
was	examined	as	a	covariate	because	it	had	been	significantly	as‐
sociated	 with	 week	 2	 outcome,	 and	 anxiety	 because	 it	 is	 often	
associated	 with	 BDZ	 use.	 Furthermore,	 baseline	 anxiety	 was	
greater	 in	psychostimulant	users	versus	non‐users	 (10.8	±	4.4	vs.	
9.2	±	4.1,	p	=	0.02).	Total	number	of	medications	used	was	greater	
in	psychostimulant	users	versus	non‐users	(4.8	±	2.4	vs.	3.4	±	2.6;	
p	<	0.001). 
3.4 | Medication categories and changes in 
symptom severity over weeks 2, 4, 6
Psychostimulant use was significantly associated with greater im‐
provement over the course of treatment including baseline IDS‐
SR30	as	a	covariate	(F(1,	176.744)	=	4.94,	p	=	0.03)	(Table	4).	Estimated	
marginal	means	were	−13.09	 for	 subjects	who	were	 taking	a	psy‐
chostimulant	versus	−9.56	for	those	who	were	not.	Total	number	of	
medications	and	anxiety	subscale	variables	were	not	significant	 in	
any	of	the	mixed	models	and	so	were	excluded	from	final	models.	
The interaction between time and medication category was not sig‐
nificant in any of the models. Figure 2 shows IDS‐SR30 changes for 
benzodiazepine	and	psychostimulant	users	and	non‐users	at	weeks	
2,	4,	and	6.
TA B L E  3  Results	of	linear	regression	analyses	examining	medication	categories	as	predictors	of	week	2	outcome	of	rTMS	for	depression:	
(a)	Models	with	baseline	IDS‐SR30	total	score	covariate	only;	(b)	Significant	models	with	baseline	anxiety	and	non‐anxiety	item	total	
covariates,	and	additional	covariates1
Medication category Overall model
Baseline IDS 
p‐value
Medication category 
p‐value
Benzodiazepine F	=	4.36;	p =	0.014 0.05 0.02* 
Psychostimulant F	=	3.45;	p =	0.034 0.12 0.05* 
SSRI F	=	1.41;	p =	0.247 0.10 0.92
SNRI F	=	1.44;	p =	0.240 0.09 0.80
Atypical	Antidepressant F	=	1.65;	p = 0.195 0.09 0.49
Atypical	Antipsychotic F	=	1.68;	p = 0.190 0.10 0.47
Anti‐Epileptic F	=	1.41;	p =	0.246 0.10 0.89
Medication 
category Model Sig. R2 Covariates and significance
Medication category statistics
Unstandardized β Std. Error t p
Benzodiazepine 0.008 0.056 Baseline	non‐anxiety	IDS	(p	=	0.019) 3.42 1.52 2.25 0.03* 
0.010 0.066 Baseline	non‐anxiety	IDS	(p	=	0.007),	
Baseline	anxiety	(p	=	0.182,	N.S.)
3.22 1.52 2.11 0.04* 
0.005 0.087 Baseline	non‐anxiety	IDS	(p	=	0.009),	
Baseline	anxiety	(p	=	0.386,	N.S.),	
Age	(p	=	0.053,	N.S.)
3.33 1.51 2.20 0.03* 
0.002 0.083 Baseline	non‐anxiety	IDS	(p	=	0.011),	
Age	(p	=	0.028)
3.47 1.50 2.31 0.02* 
Psychostimulants 0.020 0.046 Baseline	non‐anxiety	IDS	(p	=	0.034) −2.93 1.60 −1.83 0.07
0.006 0.083 Baseline	non‐anxiety	IDS	(p	=	0.004),	
Baseline	Anxiety	(p	=	0.068),	Total	
Meds	(p	=	0.093)
−4.15 1.65 −2.51 0.01** 
0.002 0.111 Baseline	IDS	(p	=	0.004),	Baseline	
Anxiety	(p	=	0.198,	N.S.),	Total	
Meds	(p	=	0.040),	Age	(p	=	0.023)
−4.44 1.64 −2.71 0.007** 
*p	≤	0.05;	**p	≤	0.01.
1 [Correction	added	on	17	April	2019,	after	 first	online	publication:	 ‘Standard	category’	
was	removed	as	a	sub‐header	under	Medication	category.]
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Considering	 a	 response	 criterion	 of	 50%	 improvement	 in	 the	
IDS‐SR30	 total	 score	 at	 week	 6,	 the	 response	 rate	 was	 lower	 in	
BDZ‐users	versus	BDZ‐non‐users	(16.4%	vs.	35.5%,	p	=	0.008),	and	
higher	in	psychostimulant	users	versus	non‐users	(39.2%	vs.	22.0%,	
p	=	0.02).
3.5 | Medication categories in relation to rTMS 
treatment parameters
Chi‐square analysis showed no significant difference between those 
who	received	solely	10	Hz	left	rTMS	treatment	compared	to	those	
who	received	1	Hz	right	sided	treatment	in	terms	of	the	frequency	
of	 benzodiazepine	 (χ2	=	1.206,	 p	=	0.33)	 or	 psychostimulant	 use	
(χ2	=	1.264,	p	=	0.40).
4  | DISCUSSION
This	 exploratory	 observational	 study	 found	 that	 benzodiazepine	
use	was	associated	with	less	improvement,	whereas	psychostimu‐
lant	use	was	associated	with	greater	improvement,	after	two	weeks	
of	rTMS	treatment	for	depression.	The	relationships	between	med‐
ication use and clinical outcome were statistically significant even 
when	 controlling	 for	 baseline	 age,	 symptom	 severity,	 and	 sever‐
ity	of	anxiety	symptoms	(p < 0.05 without correction for multiple 
comparisons).	The	week	two	results	are	of	 interest	because	most	
subjects	 (78%)	 had	 received	 standardized	 10	Hz	 rTMS	 targeting	
left	 DLPFC	 only.	 Across	 the	 entire	 six	 weeks	 of	 treatment,	 psy‐
chostimulant	use	was	associated	with	greater	improvement,	again	
after controlling for baseline variables. Treatment over the entire 
six‐week	course	involved	greater	variability;	by	week	6,	1	Hz	rTMS	
targeting	right	DLPFC	had	been	introduced	into	treatment	for	70%	
of	the	sample.	Given	that	psychostimulant	effects	were	observed	
at	week	2	and	across	six	weeks	of	treatment,	this	medication	cat‐
egory	may	be	more	likely	to	be	associated	with	rTMS	outcome	for	
depression	regardless	of	treatment	duration,	or	the	site/frequency	
of stimulation.
The	 present	 results	 suggest	 that	 BDZ	 use	 is	 associated	with	
less	 improvement	 early	 in	 the	 course	 of	 rTMS.	 (Supplementary	
analyses	 showed	 that	 a	 broader	 group	 of	GABA	 agonists,	which	
included	BDZ,	was	associated	with	poorer	six‐week	outcome.	See	
Data	S1).	There	is	evidence	of	disturbances	in	the	GABAergic	sys‐
tem	in	MDD,	including	decreased	cortical	concentrations	of	GABA,	
as	measured	by	magnetic	resonance	spectroscopy	(MRS)	(Pehrson	
&	Sanchez,	2015),	as	well	as	emerging	evidence	that	some	effec‐
tive treatments for depression are associated with enhanced or re‐
mediated	GABA	function.	One	prior	rTMS	investigation	reported	a	
trend‐level negative association between change in medial prefron‐
tal	cortex	GABA	during	a	course	of	TMS	and	daily	use	of	lorazepam	
(Dubin	 et	 al.,	 2016).	 In	 rodent	 models,	 long‐term	 administration	
of	BDZ	 is	associated	with	down‐regulatory	effects	on	GABA	sig‐
naling,	 such	as	decreases	 in	GABAA	receptor	subunit	expression,	
including	cortical	alpha‐1	mRNA	(Uusi‐Oukari	&	Korpi,	2010),	de‐
creased	alpha‐1	polypeptide	(Chen,	Huang,	Zeng,	Sieghart,	&	Tietz,	
1999;	Impagnatiello	et	al.,	1996;	Pesold	et	al.,	1997),	and	modified	
surface	dynamics	of	GABAARs	 (Gouzer,	Specht,	Allain,	Shinoe,	&	
Triller,	2014).	These	effects	 suggest	 that	 the	concurrent,	 chronic	
use	 of	 BDZ	medications	 could	 tend	 to	mitigate	 the	 probable	 in‐
creases	 in	 cortical	GABA	 signaling	 that	 appear	with	 clinically	 ef‐
fective	rTMS.
Psychostimulants	(in	use	by	31%	of	our	sample)	could	enhance	
rTMS	 treatment	 outcomes	 through	 enhancement	 of	 plasticity	 as	
catecholaminergic	agonists,	most	 likely	acting	through	adrenergic	
pathways.	NE	is	a	strong	modulator	of	cortical	plasticity,	for	exam‐
ple,	in	the	hippocampus	(Gu,	2002).	This	finding	also	is	consistent	
with	the	results	of	experiments	testing	the	effects	of	noradrenergic	
agents	on	single‐	and	paired‐pulse	TMS	paradigms.	Catecholamine	
transport inhibitors such as methylphenidate enhance the prac‐
tice	 effect	 on	 single‐pulse	 TMS‐induced	movement	 (Meintzschel	
&	 Ziemann,	 2005),	 and	 amphetamine	 enhances	 practice‐related	
changes	 in	cortical	motor	mapping	 (Tegenthoff,	Cornelius,	Pleger,	
Malin,	&	Schwenkreis,	2004).	Conversely,	the	selective	alpha‐1	ad‐
renergic	receptor	antagonist	prazosin	abolishes	the	LTP‐like	motor‐
evoked	potential	 response	 in	 the	paired‐associate	TMS	paradigm	
(Korchounov	 &	 Ziemann,	 2011).	 These	 effects	 on	 plasticity	 are	
not	mediated	by	changes	in	excitability	per	se, because the motor 
threshold	 is	not	altered	by	methylphenidate	 (Gilbert	et	al.,	2006),	
amphetamine	(Boroojerdi,	Battaglia,	Muellbacher,	&	Cohen,	2001;	
Ziemann,	Tergau,	Bruns,	Baudewig,	&	Paulus,	1997),	atomoxetine	
(Gilbert	 et	 al.,	 2006),	 guanfacine	 (Boroojerdi	 et	 al.,	 2001),	 or	 yo‐
himbine	 (Plewnia,	 Bartels,	 Cohen,	&	Gerloff,	 2001).	 It	 is	 possible	
that these plasticity‐modulating effects also are synergistic with 
rTMS,	giving	rise	to	relatively	enhanced	clinical	outcomes	for	those	
patients concurrently taking noradrenergic agonist agents.
The present results could be consistent with an interaction 
between	 stimulation	 site/frequency	 and	 medication,	 in	 which	
TA B L E  4  Medication	effects	in	linear	mixed	model	analyses	
examining	clinically	based	medication	categories	as	predictors	of	
change	in	symptom	severity	over	time	(weeks	2,	4,	and	6)2
 Denominator df F p
Psychostimulants 176.74 4.94 0.03* 
Benzodiazepine 178.06 3.00 0.09
SSRI 177.48 0.00 0.99
SNRI 177.30 0.00 0.99
Atypical	Antidepressant 177.45 0.11 0.74
Atypical	Antipsychotic 177.43 0.03 0.86
Anti‐Epileptic 177.24 0.28 0.60
Note.	 All	 models	 included	 baseline	 severity	 as	 a	 covariate.	 Change	 in	
symptom severity was assessed using the Inventory of Depressive 
Symptomatology	Self	Report	(IDS‐SR30)	(Rush	et	al.,	1996).
*p	≤	0.05.
 2 [Correction	added	on	17	April	2019,	after	first	online	publication:	the	following	changes	
have	been	made	 (1)	MOA‐based	medical	categories	are	not	 included	and	 this	has	been	
deleted	 in	 the	 table	 caption;	 and	 (2)	 ‘Standard	category’	was	 removed	as	a	 sub‐header	
under	Medication	category.]
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benzodiazepines	 counter	 and	 psychostimulants	 potentiate	 the	 ef‐
fects	of	 left‐sided	 fast	 rTMS.	Conversely,	 these	medications	might	
have	opposite	effects	in	the	context	of	right‐sided	slow	rTMS.	This	
would	be	 supported	by	 the	 finding	 that	benzodiazepine	use	 is	 as‐
sociated with less clinical benefit in the first two weeks of treat‐
ment	only,	when	most	patients	received	only	left‐sided	stimulation.	
Because treatment was not assigned in a controlled manner in this 
study,	we	cannot	definitively	address	this	question.	Future	work	is	
needed	to	examine	medication	use	and	rTMS	treatment	outcomes	in	
controlled	experimental	treatment.
We found no significant interaction between the administration 
of	antipsychotic	medication	and	rTMS	treatment	outcome	in	these	
patients. These findings are consistent with the prior work of Hu 
and	colleagues	 (2016),	who	reported	no	benefit	 from	concomitant	
quetiapine administration in Bipolar II depressed patients receiv‐
ing	rTMS,	 though	only	partially	consistent	with	the	prior	 report	of	
Schulze	 and	 colleagues	 (2017),	who	 found	 a	 non‐significant	 trend	
towards greater improvement among patients receiving theta‐burst 
rTMS	and	antipsychotic	medication.	Future	studies	should	examine	
the	 interactions	of	class	of	medications	with	different	 rTMS	treat‐
ment parameters.
4.1 | Limitations
This study is significant in that it offers the first systematic survey 
of relationships among the use of commonly prescribed medications 
and	 rTMS	treatment	outcome	 in	MDD.	Strengths	of	 the	study	are	
the	large	number	of	subjects	examined	and	the	broad	range	of	medi‐
cations	 considered.	Nevertheless,	 results	 should	 be	 interpreted	 in	
the	context	of	certain	limitations.	First,	this	study	was	observational	
and	 did	 not	 utilize	 controlled	 assignment	 to	 type(s)	 of	medication	
or	 rTMS	treatment.	There	were	significant	differences	 in	outcome	
of	those	receiving	exclusively	 left‐sided	versus	right‐sided	stimula‐
tion	at	some	point	in	the	course	of	their	rTMS	treatment,	although	
there	were	 no	 significant	 differences	 in	 benzodiazepine	 or	 stimu‐
lant use between the two treatment groups. Subjects entered the 
F I G U R E  2  Change	in	IDS	total	score	(mean	and	standard	deviation)	at	weeks	2,	4,	6	and	rates	of	response	and	remission,	for	users	versus	
non‐users	of	benzodiazepines	(a)	and	psychostimulants	(b)
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study taking medications that were prescribed on clinical grounds 
by prior treating physicians. These data suggest that groups of sub‐
jects	receiving	different	rTMS	treatment	paradigms	and/or	medica‐
tions may have had underlying neurobiological or clinical differences 
that	could	account	in	part	for	the	observed	differences	in	outcome,	
apart from the effects of treatment alone. We did not have diag‐
nostic	information	on	possible	comorbid	psychiatric	diagnoses,	nor	
a measure of the degree of treatment; either comorbid diagnoses or 
differences in treatment resistance could contribute to differences 
in	 treatment	outcome.	Second,	a	major	caveat	 is	 that	we	explored	
relationships between a large number of medication categories 
without correction for multiple comparisons. These results should 
therefore be considered as hypothesis‐generating. These results are 
novel	and	indicate	the	importance	of	future	experimental	studies	of	
drug/TMS	 interactions,	 to	 address	 both	 neurobiological	 and	 clini‐
cal effects. It remains premature to make clinical recommendations 
on	the	basis	of	the	foregoing	evidence;	however,	 this	represents	a	
future	 goal	 of	 this	 work.	 Third,	 the	 absence	 of	 significant	 results	
for the less‐often prescribed medication categories may represent 
false‐negative	 results.	Although	we	 constrained	 analyses	 to	 those	
categories	that	were	prescribed	to	at	least	20%	of	the	sample,	analy‐
ses	may	have	been	underpowered	to	detect	effects.	Fourth,	these	
results	do	not	account	for	possible	nonlinear	effects	of	medications,	
or	possible	complex	pharmacodynamic	effects	in	subjects	receiving	
medication	combinations;	therefore,	results	may	reflect	interactions	
among	 simultaneous	 medications.	 Lastly,	 we	 had	 no	 information	
on differences among subjects in their rates of metabolism for the 
drugs	prescribed	and	limited	information	on	medication	adherence,	
which made it impossible to compare pharmacodynamic and phar‐
macokinetic effects across the sample.
5  | CONCLUSION
The findings of this manuscript indicate important lines for future re‐
search.	It	is	possible	that	concomitant	medication	use	may,	depend‐
ing	on	the	drug	category	or	MOA,	impact	rTMS	treatment	outcome	
favorably	or	unfavorably.	The	present	findings,	if	replicated	with	ap‐
propriate	 controls,	 could	have	 implications	 for	 the	 concurrent	 use	
of	 psychotropic	 medications	 during	 rTMS	 treatment.	 Prospective	
hypothesis‐based studies controlling for multiple medications and 
treatment‐resistance are needed to guide decisions about use of 
common	medications	during	rTMS	treatment.
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